371 related articles for article (PubMed ID: 28116950)
21. Ceftaroline fosamil salvage therapy: an option for reduced-vancomycin-susceptible MRSA bacteraemia.
Espedido BA; Jensen SO; van Hal SJ
J Antimicrob Chemother; 2015 Mar; 70(3):797-801. PubMed ID: 25406295
[TBL] [Abstract][Full Text] [Related]
22. Assessment of invitrosynergy of daptomycin or vancomycin plus ceftaroline for daptomycin non-susceptible Staphylococcus aureus.
Hutton MA; Sundaram A; Perri MB; Zervos MJ; Herc ES
Diagn Microbiol Infect Dis; 2020 Nov; 98(3):115126. PubMed ID: 32861155
[TBL] [Abstract][Full Text] [Related]
23. Ceftaroline-heteroresistant Staphylococcus aureus.
Saravolatz SN; Martin H; Pawlak J; Johnson LB; Saravolatz LD
Antimicrob Agents Chemother; 2014 Jun; 58(6):3133-6. PubMed ID: 24637680
[TBL] [Abstract][Full Text] [Related]
24. In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
Saravolatz L; Pawlak J; Johnson L
Antimicrob Agents Chemother; 2010 Jul; 54(7):3027-30. PubMed ID: 20404122
[TBL] [Abstract][Full Text] [Related]
25. Phage-antibiotic synergy against daptomycin-nonsusceptible MRSA in an
Kunz Coyne AJ; Bleick C; Stamper K; Kebriaei R; Bayer AS; Lehman SM; Rybak MJ
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0138823. PubMed ID: 38376187
[TBL] [Abstract][Full Text] [Related]
26. Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline.
Sakoulas G; Moise PA; Casapao AM; Nonejuie P; Olson J; Okumura CY; Rybak MJ; Kullar R; Dhand A; Rose WE; Goff DA; Bressler AM; Lee Y; Pogliano J; Johns S; Kaatz GW; Ebright JR; Nizet V
Clin Ther; 2014 Oct; 36(10):1317-33. PubMed ID: 25017183
[TBL] [Abstract][Full Text] [Related]
27. Activity of ceftaroline against extracellular (broth) and intracellular (THP-1 monocytes) forms of methicillin-resistant Staphylococcus aureus: comparison with vancomycin, linezolid and daptomycin.
Mélard A; Garcia LG; Das D; Rozenberg R; Tulkens PM; Van Bambeke F; Lemaire S
J Antimicrob Chemother; 2013 Mar; 68(3):648-58. PubMed ID: 23188792
[TBL] [Abstract][Full Text] [Related]
28. In vitro ceftaroline combinations against meticillin-resistant Staphylococcus aureus.
García AB; Candel FJ; López L; Chiarella F; Viñuela-Prieto JM
J Med Microbiol; 2016 Oct; 65(10):1119-1122. PubMed ID: 27553740
[TBL] [Abstract][Full Text] [Related]
29. Daptomycin in Combination with Ceftolozane-Tazobactam or Cefazolin against Daptomycin-Susceptible and -Nonsusceptible Staphylococcus aureus in an In Vitro, Hollow-Fiber Model.
Smith JR; Arya A; Yim J; Barber KE; Hallesy J; Singh NB; Rybak MJ
Antimicrob Agents Chemother; 2016 Jul; 60(7):3970-5. PubMed ID: 27090172
[TBL] [Abstract][Full Text] [Related]
30. Successful treatment with daptomycin and ceftaroline of MDR Staphylococcus aureus native valve endocarditis: a case report.
Duss FR; Garcia de la Mària C; Croxatto A; Giulieri S; Lamoth F; Manuel O; Miró JM
J Antimicrob Chemother; 2019 Sep; 74(9):2626-2630. PubMed ID: 31298264
[TBL] [Abstract][Full Text] [Related]
31. Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus using an in vitro model.
Zhanel GG; Rossnagel E; Nichol K; Cox L; Karlowsky JA; Zelenitsky S; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2011 Jun; 66(6):1301-5. PubMed ID: 21429940
[TBL] [Abstract][Full Text] [Related]
32. Pre-clinical Impact of the Synergistic Mechanism of Daptomycin and Ceftaroline on Patients with Methicillin-resistant Staphylococcus aureus Bacteremia Infections.
Eliazar J; Johnson T; Chbib C
Curr Rev Clin Exp Pharmacol; 2021; 16(4):296-299. PubMed ID: 33423652
[TBL] [Abstract][Full Text] [Related]
33. A comparison of daptomycin alone and in combination with ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bacteremia complicated by septic pulmonary emboli.
Morrisette T; Lagnf AM; Alosaimy S; Rybak MJ
Eur J Clin Microbiol Infect Dis; 2020 Nov; 39(11):2199-2203. PubMed ID: 32535805
[TBL] [Abstract][Full Text] [Related]
34. In vitro activity of ceftaroline in combination with other antimicrobials active against Staphylococcus spp.
Gil Romero Y; Gómez-Garcés JL
Enferm Infecc Microbiol Clin (Engl Ed); 2020 Jan; 38(1):25-27. PubMed ID: 31072712
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the in vivo efficacy of ceftaroline fosamil, vancomycin and daptomycin in a murine model of methicillin-resistant Staphylococcus aureus bacteraemia.
García P; Moscoso M; Fernández MC; Fuentes-Valverde V; Pérez A; Bou G
Int J Antimicrob Agents; 2023 Jul; 62(1):106836. PubMed ID: 37150362
[TBL] [Abstract][Full Text] [Related]
36. Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations.
Steed ME; Vidaillac C; Rybak MJ
Antimicrob Agents Chemother; 2010 Dec; 54(12):5187-92. PubMed ID: 20921318
[TBL] [Abstract][Full Text] [Related]
37. Bactericidal activity of ceftaroline, vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus isolates from cancer patients.
Rolston KVI; Jamal M; Nesher L; Raad I; Rice SA; Rybak MJ; Prince RA
J Glob Antimicrob Resist; 2019 Jun; 17():16-18. PubMed ID: 30844496
[No Abstract] [Full Text] [Related]
38. Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals.
Sader HS; Jones RN; Rossi KL; Rybak MJ
J Antimicrob Chemother; 2009 Nov; 64(5):1024-8. PubMed ID: 19744978
[TBL] [Abstract][Full Text] [Related]
39. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.
LaPlante KL; Rybak MJ
Antimicrob Agents Chemother; 2004 Dec; 48(12):4665-72. PubMed ID: 15561842
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
Leonard SN; Rybak MJ
J Antimicrob Chemother; 2009 Jan; 63(1):155-60. PubMed ID: 18984644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
